Macular Degeneration Research
Macular degeneration research focuses on a leading cause of vision loss in older adults.
As we age, we become more susceptible to developing eye conditions, including age-related macular degeneration (AMD), a disease characterized by a loss of vision in the macula, the center of the retina and the area of central vision. In the United States, AMD is the most common cause of vision loss and blindness for adults over the age of 50. In addition, patients with diabetes are at increased risk of developing macular degeneration. Macular degeneration research focuses on several key approaches for treatment of AMD.
Types of macular degeneration
There are two types of age-related macular degeneration, nonexudative (or dry) and exudative (or wet):
- Dry AMD: This is the more common form of the disease, and is characterized by a deterioration of the macula itself.
- Wet AMD: This form of the disease results from abnormal blood vessels that rupture, leaking fluid into the macula, a condition known as choroidal neovascularization.
Dry macular degeneration research
Our recent and ongoing dry macular degeneration research focuses on several approaches, including:
- The potential of vitamin supplements to decrease the risk of vision loss in some patients
- Devices to evaluate the progression of and monitor changes in AMD
- Genetic analysis studies
- Macular degeneration drug research testing the efficacy of these medications
Wet macular degeneration drug research
Our recent and ongoing wet macular degeneration research focuses on several macular degeneration drug studies, including:
- Studies that test efficacy and safety
- Studies that compare macular degeneration drugs
- Studies focused on drug maintenance and macular degeneration drug delivery systems
Advanced treatment for macular degeneration
Henry Ford retinal specialists have extensive experience in macular degeneration treatment, including complex cases. In addition, our team works closely with Henry Ford Medical Group physicians in other departments, providing multidisciplinary, coordinated care for those patients who need it. Our patients have access to advanced diagnostic tests and treatment and, if eligible, related clinical trials.